title: Sustainability of Intraocular Pressure Reduction of Travoprost Ophthalmic Solution in Subjects with Normal Tension Glaucoma.
abstract: BACKGROUND
  We examined the sustainability of the intraocular pressure (IOP)-lowering efficacy of travoprost (0.004%) ophthalmic solution in subjects with normal tension glaucoma (NTG).
  
  
  METHODS
  Travoprost ophthalmic solution was given once daily at 9 PM to subjects with newly diagnosed NTG or with NTG who had not received any ocular hypotensives within the previous 30 days. IOP was measured at three time points (9 AM, 1 PM, and 5 PM) at baseline and week 12 visits, and at one time point (9 AM) at week 4 and week 8 visits. Conjunctival hyperemia, superficial punctate keratopathy, and other adverse events were evaluated during the observation period.
  
  
  RESULTS
  Thirty subjects (12 males and 18 females; mean age 65.6 years) from 32 subjects enrolled were included in the efficacy analysis. The mean IOPs (±standard deviation) of 16.6 ± 1.4, 15.7 ± 1.8, and 15.7 ± 2.2 mmHg at 9 AM, 1 PM, and 5 PM, respectively, at baseline reduced significantly to the mean IOPs of 13.0 ± 1.8, 12.7 ± 1.8, and 12.8 ± 1.6 mmHg, respectively, at week 12 (P < 0.0001 for every time point). Together with the mean IOPs of 13.4 ± 1.9 mmHg at week 4 and 13.2 ± 1.9 mmHg at week 8, the pooled IOP during the observation period for up to 12 weeks showed a statistically and clinically significant reduction of IOP at 9 AM. (3.4 mmHg or 20.3% reduction from baseline, P < 0.0001). There were no adverse events leading to treatment discontinuation.
  
  
  CONCLUSIONS
  This multi-center collaborative study suggests that IOP-lowering efficacy of travoprost ophthalmic solution persists during the day at the clinically relevant level in subjects with NTG.
  
  
  BACKGROUND
  Alcon Japan Ltd.
  
  
  BACKGROUND
  University Hospital Medical Information Network, UMIN ID: 000011621.
authors: Department of Ophthalmology, Okayama University Graduate School of Medicine, Shikata-cho, Kita-ku, Okayama, Japan. tomokoum@gmail.com.
authors: Tomoko
authors: T
authors: Naito
authors: Sumitomo Besshi Hospital, Oji-cho, Niihama, Ehime, Japan.
authors: Shinichi
authors: S
authors: Okuma
authors: Nagayama Eye Clinic, Goban-cho, Kasaoka, Okayama, Japan.
authors: Mikio
authors: M
authors: Nagayama
authors: Department of Ophthalmology, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, Japan.
authors: Shiro
authors: S
authors: Mizoue
authors: Ozaki Eye Hospital, Kamezaki, Hyuga, Miyazaki, Japan.
authors: Mineo
authors: M
authors: Ozaki
authors: Sumitomo Besshi Hospital, Oji-cho, Niihama, Ehime, Japan.|Department of Ophthalmology, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, Japan.
authors: Koji
authors: K
authors: Namiguchi
authors: Sumitomo Besshi Hospital, Oji-cho, Niihama, Ehime, Japan.
authors: Kazuhisa
authors: K
authors: Miyamoto
authors: Department of Ophthalmology, Shimane University Faculty of Medicine, 89-1 Enya, Izumo, Shimane, Japan.|Division of Ophthalmology, Matsue Red Cross Hospital, 200 Horomachi, Matsue, Shimane, Japan.
authors: Masaki
authors: M
authors: Tanito
authors: Yoshikawa Eye Clinic, Nakamachi, Machida, Tokyo, Japan.
authors: Keiji
authors: K
authors: Yoshikawa
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D007564:Japan; D057066:Low Tension Glaucoma / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000008:administration & dosage; D014065:Tonometry, Ocular; D000069557:Travoprost / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000959:Antihypertensive Agents; D009883:Ophthalmic Solutions; D000069557:Travoprost
keywords: IOP-lowering; Intraocular pressure (IOP); Normal tension glaucoma; Sustainability; Travoprost